Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows provided by operating activities:
Net income	$ 2,344	$ 3,506
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	247	253
Amortization of operating lease right-of-use assets	374	364
Stock based compensation	290	162
Change in deferred tax assets	(402)	421
Realized gain on sale of investment in iBio Stock	0	(56)
Unrealized loss on investment in iBio Stock	48	51
Other, net	(4)	16
Changes in operating assets and liabilities:
Accounts receivable, net	(394)	(948)
Inventories	(1,401)	(3,321)
Other assets	(239)	(158)
Accounts payable	1,285	2,201
Accrued expenses and other liabilities	(385)	212
Operating lease obligations	(375)	(365)
Net cash provided by operating activities	1,388	2,338
Cash flows from investing activities:
Purchase of property and equipment	(451)	(150)
Proceeds from sale of iBio Stock	0	96
Proceeds from sale of machinery and equipment	21	0
Net cash used in investing activities	(430)	(54)
Cash flows from financing activities:
Advances under revolving credit facility	42,664	41,758
Proceeds from exercise of employee stock options	7	14
Repayments of advances under revolving credit facility	(42,109)	(43,288)
Repayments under term note payables	(1,466)	(990)
Repayments under finance lease obligations	0	(75)
Net cash used in financing activities	(904)	(2,581)
Net decrease in cash	54	(297)
Cash at beginning of period	210	402
Cash at end of period	264	105
Interest paid	90	176
Income taxes paid	446	408
Supplemental disclosures of non-cash flow transactions:
Amount owed on purchase of property and equipment	$ 84	$ 50